New drug duo targets Hard-to-Treat lymphomas

NCT ID NCT05627245

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests the safety and best dose of combining two drugs, tazemetostat and belinostat, for people with lymphoma that has returned or stopped responding to standard treatments. The study includes about 48 adults with various types of non-Hodgkin lymphoma. Researchers want to see if this combination can shrink or stabilize the cancer, and they will monitor side effects closely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma diffuse large B-cell lymphoma germinal center B-cell type follicular lymphoma non-Hodgkin lymphoma primary cutaneous T-cell non-Hodgkin lymphoma refractory malignant neoplasm relapsed/refractory diffuse large B-cell lymphoma T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

New York, New York, 10032, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
University of California Davis Comprehensive Cancer Center

Sacramento, California, 95817, United States
University of Kansas Cancer Center

Kansas City, Kansas, 66160, United States
University of Kansas Clinical Research Center

Fairway, Kansas, 66205, United States
University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, 66205, United States
University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States
VCU Massey Comprehensive Cancer Center

Richmond, Virginia, 23298, United States
Yale University

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.